Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SDCBP | O00560 | 3/20 | 0.40 |
| ▸ | SDC2 | P34741 | 3/20 | 0.40 |
| ▸ | VHL | P40337 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178898 | 0.91 | LMNA (0.43) | SDCBPSDC2DGAT1CSGALNACT1LMNA | |
| SCHEMBL2178892 | 0.91 | LMNA (0.43) | SDCBPSDC2DGAT1CSGALNACT1LMNA | |
| SCHEMBL2181264 | 0.87 | LMNA (0.52) | GAAATMMAPK1ALDH1A1PKM | |
| SCHEMBL2181198 | 0.85 | LMNA (0.47) | SDCBPSDC2DGAT1CSGALNACT1LMNA | |
| SCHEMBL2182061 | 0.85 | LMNA (0.47) | SDCBPSDC2DGAT1CSGALNACT1LMNA | |
| SCHEMBL2178369 | 0.85 | DGAT1 (0.50) | GAAATMMAPK1ALDH1A1PKM | |
| SCHEMBL2176524 | 0.83 | LMNA (0.46) | GAAATMMAPK1SDCBPSDC2 | |
| SCHEMBL2176529 | 0.83 | LMNA (0.46) | GAAATMMAPK1SDCBPSDC2 | |
| SCHEMBL2176748 | 0.83 | KDR (0.49) | SDCBPSDC2DGAT1CSGALNACT1LMNA | |
| SCHEMBL2177864 | 0.83 | KDR (0.49) | SDCBPSDC2DGAT1CSGALNACT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | claimed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | claimed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | claimed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | claimed |
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | disclosed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | DGAT1, DGAT2, LCAT | GAA 178/4885ATM 3537/4885MAPK1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.